Predictive Oncology Inc
POAI5.950USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.56MMarket Cap
LossP/E TTM
More Details of Predictive Oncology Inc Company
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Predictive Oncology Inc Info
Ticker SymbolPOAI
Company namePredictive Oncology Inc
IPO dateDec 18, 2009
CEOVennare (Raymond F)
Number of employees23
Security typeOrdinary Share
Fiscal year-endDec 18
Address91 43Rd Street
CityPITTSBURGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code15201
Phone14124321500
Websitehttps://predictive-oncology.com/
Ticker SymbolPOAI
IPO dateDec 18, 2009
CEOVennare (Raymond F)
Company Executives of Predictive Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-26.95%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-26.95%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
Blacher (Joshua)
0.04%
Vennare (Raymond F)
0.04%
Other
95.15%
Shareholders
Shareholders
Proportion
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
Blacher (Joshua)
0.04%
Vennare (Raymond F)
0.04%
Other
95.15%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.19%
Corporation
1.73%
Investment Advisor/Hedge Fund
0.15%
Other
94.93%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
37
7.39K
0.21%
-26.00K
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Blacher (Joshua)
6.47K
0.85%
+6.47K
--
Sep 09, 2025
Vennare (Raymond F)
8.81K
1.16%
+8.33K
+1753.89%
Sep 09, 2025
Nuzum (Charles Lee Sr)
6.31K
0.83%
+4.31K
+216.25%
Sep 09, 2025
St Clair (Gregory Sr)
5.72K
0.75%
+4.31K
+305.17%
Sep 09, 2025
Chung-Welch (Nancy)
5.60K
0.73%
+4.31K
+334.78%
Sep 09, 2025
Handley (Daniel E)
5.45K
0.71%
+4.31K
+379.91%
Sep 09, 2025
Hawryluk (Matthew)
4.95K
0.65%
+4.31K
+681.20%
Sep 09, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Date
Type
Ratio
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Predictive Oncology Inc?
The top five shareholders of Predictive Oncology Inc are:
Blacher (Joshua) holds 6.47K shares, accounting for 0.85% of the total shares.
Vennare (Raymond F) holds 8.81K shares, accounting for 1.16% of the total shares.
Nuzum (Charles Lee Sr) holds 6.31K shares, accounting for 0.83% of the total shares.
St Clair (Gregory Sr) holds 5.72K shares, accounting for 0.75% of the total shares.
Chung-Welch (Nancy) holds 5.60K shares, accounting for 0.73% of the total shares.
Blacher (Joshua) holds 6.47K shares, accounting for 0.85% of the total shares.
Vennare (Raymond F) holds 8.81K shares, accounting for 1.16% of the total shares.
Nuzum (Charles Lee Sr) holds 6.31K shares, accounting for 0.83% of the total shares.
St Clair (Gregory Sr) holds 5.72K shares, accounting for 0.75% of the total shares.
Chung-Welch (Nancy) holds 5.60K shares, accounting for 0.73% of the total shares.
What are the top three shareholder types of Predictive Oncology Inc?
The top three shareholder types of Predictive Oncology Inc are:
Luo (Weiyu)
SLN Capital Ltd
Diametric Capital
Luo (Weiyu)
SLN Capital Ltd
Diametric Capital
How many institutions hold shares of Predictive Oncology Inc (POAI)?
As of 2025Q3, 37 institutions hold shares of Predictive Oncology Inc, with a combined market value of approximately 7.39K, accounting for 0.21% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.72%.
What is the biggest source of revenue for Predictive Oncology Inc?
In --, the -- business generated the highest revenue for Predictive Oncology Inc, amounting to -- and accounting for --% of total revenue.
